Novo Holdings

Novo Holdings, established in 1999 and based in Copenhagen, is the asset manager for the Novo Nordisk Foundation, overseeing its wealth and investments. The company primarily focuses on the life sciences sector, investing across various stages of company development, from early-stage ventures to established firms. Novo Holdings also manages a diversified portfolio of financial investments, including equity and fixed income securities. It is recognized as a leading life science investor globally and aims to generate long-term value to support the Foundation's grant obligations for medical and scientific research. Additionally, it plays a pivotal role in the Novo Group, maintaining a significant influence over its associated companies, including Novo Nordisk and Novozymes, while ensuring compliance with the group’s shared values and management principles. Through initiatives like Novo Seeds, the firm supports early-stage applied research in Scandinavia, further solidifying its commitment to advancing health and welfare through strategic investments.

Tiba Aynechi

Partner

Nis Bjørnholt Bak

Principal

Michael Bauer

Venture Partner

Raymond Camahort

Principal at Novo Ventures

Ross Castillo

Associate

Emmanuelle Coutanceau

Partner

Kartik Dharmadhikari

Partner, Bioindustrial Investments

Nik Economopoulos

Associate

Aleks Engel

Partner, Novo Holdings (Novo Seeds) and Director, REPAIR Impact Fund

Anna Fan

Senior Partner, Life Sciences Operating Committee, Venture Investments, Venture Investments (US) Inc

Thomas Grotkjær

Investor and Principal

Kenneth Harrison Ph.D

Senior Partner, Novo Ventures

Stephen van Helden

Principal, Bioindustrial Investments, Growth Investments

Johan Hueffer

Senior Partner, Principal Investments

Noel Jee

Partner

Morten Beck Jørgensen

Managing Partner

Amit Kakar

Managing Partner and Head of Novo Holdings Asia

Navjeewan Khosla

Partner, Novo Holdings Equity Asia

Max Klement

Principal, Venture Investments

Nilesh Kumar

Partner

Abhijeet Lele

Senior Partner and Head of US Principal Investments

Jeffrey Low, MD

Principal

Heather Ludvigsen

Venture Auditor

Joe Markson

Associate

Nafise Masoumi

Associate

Peter Moldt

Partner

Jack Nielsen

Partner

Jørgen Søberg Petersen

Senior Partner, Seed Investments

Marcus REMMERS

Partner, Bioindustrial Investments

Joao Ribas

Principal, Seed Investments

Natalie Sacks

Venture Partner, Venture Investments

Naveed Siddiqi

Senior Partner, Venture Investments

Eric Snyder

Partner

Jim Trenkle

Partner, Venture Investments

Matthias Vinther

Senior Associate

Past deals in Nutrition

Kate Farms

Series C in 2022
Kate Farms, Inc. specializes in the production of plant-based meal replacement shakes and tube feeding solutions, catering to individuals with various dietary and medical needs. Established in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company has become a leader in vegan nutrition. Its enteral formulas are designed for easy digestion and are free from common allergens such as dairy, soy, and gluten, making them suitable for a wide range of patients. Clinicians have reported positive outcomes, including reduced gastrointestinal intolerance and improved nutritional status for users. By combining advanced scientific research with natural ingredients, Kate Farms aims to enhance health and well-being, empowering caregivers, healthcare professionals, and patients to choose effective nutritional solutions. The company's commitment to quality ensures that everyone has access to nourishing options that promote overall health.

BIOMILQ

Series A in 2021
We leverage our patent-pending technology to produce nutritionally equivalent breastmilk from cultured human mammary cells. With Biomilq, families can achieve the recommended six months of exclusive breastfeeding while alleviating the climate impacts of bovine-based infant formula.

Noom

Series F in 2021
Noom, Inc. is a mobile health coaching company that focuses on preventing and managing chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York, with additional offices in Seoul and Tokyo, Noom combines technology with human empathy to facilitate behavior change. Its platform includes evidence-based curricula, trained cognitive behavior coaches, and mobile tracking tools, allowing users to engage in personalized health management. Noom's direct-to-consumer applications have successfully reached over 47 million users globally, and the company has expanded its offerings to include programs for pre-hypertension and diabetes management, as well as its original weight loss initiatives. By leveraging the recognition from the CDC's Diabetes Prevention Program, Noom aims to provide scalable solutions for individuals seeking to improve their health outcomes.

The Protein Brewery

Series A in 2020
The Protein Brewery B.V., founded in 2019 and based in Breda, the Netherlands, specializes in developing and manufacturing animal-free protein products through innovative fermentation technologies. As a spin-out from BioscienZ, the company focuses on producing Fermotein, a fungi-based protein designed to replace traditional animal proteins. This sustainable production method utilizes significantly less land and water compared to conventional agriculture, while delivering proteins that maintain essential amino acids, vitamins, and minerals necessary for a balanced diet. The Protein Brewery aims to provide consumers with high-quality protein-integrated foods that do not compromise on taste or performance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.